Clinical and Pharmacological Hallmarks of Rifapentine’s Use in Diabetes Patients With Active and Latent Tuberculosis: Do We Know Enough?

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s146506
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Roma Health: Do We Know Enough?

International Journal of Public Health
EnvironmentalPublic HealthHealthOccupational Health
2019English

Short-Course Chemotherapy With TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2011English

Ketamine or Ketofol: Do We Have Enough Evidence to Know Which One to Use?

Academic Emergency Medicine
MedicineEmergency Medicine
2017English

Restoration on Abandoned Tropical Pasturelands—do We Know Enough?

Journal for Nature Conservation
Landscape ConservationEcologyNature
2004English

Antifungal Clinical Trials and Guidelines: What We Know and Do Not Know

Cold Spring Harbor perspectives in medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?

American Journal on Addictions
MedicineClinical PsychologyPsychiatryMental Health
2010English

Antinuclear and Antiretinal Antibodies in Uveitis Associated With Active and Latent Tuberculosis

Acta Ophthalmologica
MedicineOphthalmology
2018English

Cytological and Cytometric Analysis of Oral Mucosa in Patients With Alzheimer’s and Parkinson’s Disease

Neuropsychiatric Disease and Treatment
2018English

Translation-Memory (TM) Research: What Do We Know and How Do We Know It?

Hermes (Denmark)
LinguisticsLanguageCommunication
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy